• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌危险因素分析及临床预后模型的建立

Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model.

作者信息

Ge Xin-Yu, Sun Ming-Chen, Wang Tian-Yi, Wang Xi-Min, Liu Gang, Yang Tao, Lu Yi-Ming, Wang Wei

机构信息

First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.

Jinzhou Medical University, Jinzhou, Liaoning, China.

出版信息

Front Oncol. 2023 Mar 22;13:1067353. doi: 10.3389/fonc.2023.1067353. eCollection 2023.

DOI:10.3389/fonc.2023.1067353
PMID:37035138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10073455/
Abstract

Liver cancer is a common malignancy of the digestive system. Hepatocellular carcinoma (HCC) accounts for the most majority of these tumors and it has brought a heavy medical burden to underdeveloped countries and regions. Many factors affect the prognosis of HCC patients, however, there is no specific statistical model to predict the survival time of clinical patients. This study derived a risk factor signature of HCC and reliable clinical prediction model by statistically analyzing The Surveillance, Epidemiology, and End Results (SEER) database patient information using an open source package in the python environment.

摘要

肝癌是消化系统常见的恶性肿瘤。肝细胞癌(HCC)在这些肿瘤中占绝大多数,给欠发达国家和地区带来了沉重的医疗负担。许多因素影响HCC患者的预后,然而,目前尚无特定的统计模型来预测临床患者的生存时间。本研究通过在Python环境中使用开源软件包对监测、流行病学和最终结果(SEER)数据库患者信息进行统计分析,得出了HCC的危险因素特征和可靠的临床预测模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/10073455/200cfd4f0526/fonc-13-1067353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/10073455/da475aab9ddf/fonc-13-1067353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/10073455/200cfd4f0526/fonc-13-1067353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/10073455/da475aab9ddf/fonc-13-1067353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1452/10073455/200cfd4f0526/fonc-13-1067353-g002.jpg

相似文献

1
Analysis of risk factors of hepatocellular carcinoma and establishment of a clinical prognosis model.肝细胞癌危险因素分析及临床预后模型的建立
Front Oncol. 2023 Mar 22;13:1067353. doi: 10.3389/fonc.2023.1067353. eCollection 2023.
2
Short-term prognosis for hepatocellular carcinoma patients with lung metastasis: A retrospective cohort study based on the SEER database.基于 SEER 数据库的回顾性队列研究:肝癌合并肺转移患者的短期预后
Medicine (Baltimore). 2022 Nov 11;101(45):e31399. doi: 10.1097/MD.0000000000031399.
3
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.基于机器学习和 HCV 状态调整的肝硬化肝细胞癌个体化监测
J Hepatol. 2020 Dec;73(6):1434-1445. doi: 10.1016/j.jhep.2020.05.052. Epub 2020 Jun 29.
4
Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model.基于机器学习模型识别手术联合化疗有生存获益的肝细胞癌患者。
World J Surg Oncol. 2022 Dec 1;20(1):377. doi: 10.1186/s12957-022-02837-2.
5
Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.肝胆细胞癌的临床病理特征、治疗、生存和预后因素:基于 SEER 数据库的列线图开发及多中心研究验证。
Eur J Surg Oncol. 2022 Jul;48(7):1559-1566. doi: 10.1016/j.ejso.2022.01.023. Epub 2022 Jan 31.
6
Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.肝细胞癌的生存改善和预后:SEER 数据库分析。
BMC Cancer. 2021 Oct 29;21(1):1157. doi: 10.1186/s12885-021-08904-3.
7
Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database.婚姻状况对接受手术切除治疗的肝细胞癌患者生存情况的影响:对监测、流行病学和最终结果(SEER)数据库中13408例患者的分析
Oncotarget. 2016 Nov 29;7(48):79442-79452. doi: 10.18632/oncotarget.12722.
8
The impact of liver fibrosis on microvascular invasion and prognosis of hepatocellular carcinoma with a solitary nodule: a Surveillance, Epidemiology, and End Results (SEER) database analysis.肝纤维化对孤立性结节肝细胞癌微血管侵犯及预后的影响:监测、流行病学和最终结果(SEER)数据库分析
Ann Transl Med. 2021 Aug;9(16):1310. doi: 10.21037/atm-21-3731.
9
A Real-World Study of Prognosis of N0M0 Hepatocellular Carcinoma with Hepatic Resection Based on SEER Database.基于监测、流行病学和最终结果(SEER)数据库的N0M0期肝细胞癌肝切除术后预后的真实世界研究
Gastroenterol Res Pract. 2020 Apr 1;2020:2357840. doi: 10.1155/2020/2357840. eCollection 2020.
10
A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis.一个来自监测、流行病学和最终结果(SEER)数据库的实用列线图,用于预测有淋巴结转移的肝细胞癌患者的预后。
Ann Palliat Med. 2021 Apr;10(4):3847-3863. doi: 10.21037/apm-20-1876. Epub 2021 Mar 16.

引用本文的文献

1
Dynamic conditional survival nomogram for primary hepatocellular carcinoma: a population-based analysis.原发性肝细胞癌的动态条件生存列线图:一项基于人群的分析。
Discov Oncol. 2025 May 21;16(1):854. doi: 10.1007/s12672-025-02642-9.
2
Rare Coexisting Hepatocellular and Gallbladder Carcinomas: A Case Report.罕见的肝细胞癌与胆囊癌并存:一例报告
Am J Case Rep. 2025 May 7;26:e946739. doi: 10.12659/AJCR.946739.
3
Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort.

本文引用的文献

1
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies.非酒精性脂肪性肝病(NAFLD)、2型糖尿病与非病毒性肝癌:病理生理机制及新治疗策略
Biomedicines. 2023 Feb 6;11(2):468. doi: 10.3390/biomedicines11020468.
2
Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer.淋巴结比率是手术治疗的早发性胰腺癌的一个更优预测指标。
Front Oncol. 2022 Sep 2;12:975846. doi: 10.3389/fonc.2022.975846. eCollection 2022.
3
Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.
手术对原发性肝癌患者总生存和癌症特异性生存的影响:一项基于监测、流行病学和最终结果(SEER)队列倾向评分匹配法的研究
Medicine (Baltimore). 2025 Feb 21;104(8):e41521. doi: 10.1097/MD.0000000000041521.
用于肝细胞癌成像的对比剂:价值与进展
Front Oncol. 2022 Jun 2;12:921667. doi: 10.3389/fonc.2022.921667. eCollection 2022.
4
Transcriptome changes in ERGIC3-knockdown hepatocellular carcinoma cells: ERGIC3 is a novel immune function related gene.内质网钙库蛋白 3 敲低肝癌细胞的转录组变化:内质网钙库蛋白 3 是一种新的免疫功能相关基因。
PeerJ. 2022 May 17;10:e13369. doi: 10.7717/peerj.13369. eCollection 2022.
5
Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.BET 抑制剂处理的 HepG2 细胞的综合转录组谱分析。
PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
6
Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma.预测肝细胞癌术后患者预后的预测模型的开发与验证
Int J Gen Med. 2022 Apr 5;15:3625-3637. doi: 10.2147/IJGM.S351265. eCollection 2022.
7
Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment.DTL 在肝细胞癌中的作用及其对肿瘤微环境的影响。
Front Immunol. 2022 Mar 22;13:834606. doi: 10.3389/fimmu.2022.834606. eCollection 2022.
8
A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.POLE 基因在肝细胞癌中的预后分析。
BMC Cancer. 2022 Feb 21;22(1):197. doi: 10.1186/s12885-022-09284-y.
9
Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.BMI1 在肝细胞癌的发生、进展和治疗中的作用。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211070689. doi: 10.1177/15330338211070689.
10
Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with NAFLD.丝氨酸棕榈酰转移酶长链亚基3与非酒精性脂肪性肝病患者的肝细胞癌有关。
Mol Clin Oncol. 2022 Feb;16(2):55. doi: 10.3892/mco.2021.2488. Epub 2021 Dec 28.